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Chen Changxi, MM,† Zhao Chuhuan, MM,† and Gao Zhan, MM†Objective: To investigate the role of thyroid hormones
and other factors in acute aortic dissection and an associa-
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Design: A retrospective analysis.
Setting: A university-afﬁliated cardiac center.
Participants: A total of 151 patients with aortic dissection
admitted to the authors’ hospital between January 2011 and
May 2015.
Intervention: None.
Measurements and Results: The total in-hospital mortal-
ity rate was 12.6%. Triiodothyronine (T3) level was lower in
nonsurviving than surviving patients (0.8  0.3 v 1.0  0.4
nmol/L, po 0.05). T3 independently predicted in-hospital
mortality (hazard ratio [HR] 0.07, 95% CI 0.01-0.43, po 0.01)
and in-hospital acute renal failure (HR 0.22, 0.05-0.89,
po 0.05) for all patients. Other independent predictors of
in-hospital mortality were pericardial effusion (HR 8.18, 2.11-
31.67, po 0.01), conservative treatment (HR 82.12, 12.49-
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Journal of Cardiothoracic(HR 3.86, 1.06-14.09, po 0.05). Inpatient conservative treat-
ment, T3 (HR 0.01, 0.00-0.18, po 0.01) as well as pericardial
effusion (HR 11.80, 2.46-56.59, po 0.01), Stanford type-A
dissection (HR 22.35, 3.15-158.40, po 0.01), and in-hospital
acute renal failure (HR 16.95, 2.04-140.86, po 0.01) were
predictors for in-hospital mortality. In nonconservatively
treated patients, T3 (HR 0.02, 0.00-0.88, po 0.05) as well
as cardiac care unit stay (HR 0.74, 0.59-0.94, po 0.01) and
postoperative acute renal failure (HR 21.32, 3.07-147.88,
po 0.01) were predictors for in-hospital mortality.
Conclusion: T3 was downregulated in acute aortic dis-
section. Low T3 level was a risk factor for in-hospital death
and acute renal failure in patients with acute aortic dissec-
tion.
& 2016 The Authors. Published by Elsevier Inc. All rights
reserved.
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ACUTE AORTIC DISSECTION is a catastrophic cardiovas-cular emergency; its in-hospital mortality rate is as high as
52%.1 However, in “stable” patients, usually those in the
chronic phase, 30-day and 5-year mortality could be as low
as 5.3% and 18%, respectively.2,3 Acute renal failure with
acute aortic dissection, which is caused by either general
circulatory collapse or renal ischemia due to renal artery
dissection,4 signiﬁcantly increases in-hospital mortality for
patients with acute aortic dissection. To distinguish high-
risk patients and improve clinical outcomes, numerous risk
factors have been identiﬁed by previous researchers.5 Some
risk factors are related to patients’ general condition, such as
age, hypotension, and past medical history; some are related
to vital organ malperfusion or systemic circulatory collapse,
such as stroke, myocardial infarction, and pericardial
tamponade. Some are biomarkers reﬂecting stress status
and inﬂammatory reaction,6 including matrix metalloprotei-
nases and soluble elastin fragments; however, thesebiomarkers are nonspeciﬁc and cannot be tested in the
clinical laboratory.
Triiodothyronine (T3) is a well-known risk factor in multiple
clinical scenarios. It was ﬁrst reported in critically ill patients
admitted to intensive care units (ICUs)7 and now can be found in
various life-threatening conditions, such as respiratory failure, acute
myocardial infarction, severe sepsis, trauma, etc.8-12 Under such
critical conditions, thyroid hormone metabolism can be profoundly
changed in patients without previously diagnosed intrinsic thyroid
disease, including low serum triiodothyronine (T3) level, normal or
low thyroxine (T4) level, and normal or low thyroid-stimulating
hormone (TSH) level.13,14 The magnitude of those changes has
been associated with disease severity and clinical outcome.15,16 The
pathophysiologic mechanism underlying the association between
T3 and critical illness has not been elucidated fully; it generally is
considered an adaptive self-protective physiologic response rather
than a maladaptive response requiring treatment.7
Nevertheless, T3 and acute aortic dissection outcomes have
not been reported previously. Gutierrez et al17 reported that T3
level was not changed in aortic dissection patients, but both
acute and chronic aortic dissection patients were enrolled in
this small sample size (n ¼ 28) research, and the relationship
between T3 and clinical outcome was not investigated. There-
fore, the authors investigated T3 level in patients with acute
aortic dissection and its predictive value for in-hospital out-
come as well as other risk factors.
MATERIALS AND METHODS
Subjects and Data Collection
Between January 2011 and May 2015, patients diagnosed
with acute aortic dissection at the First Afﬁliated Hospital
of Wenzhou Medical University were enrolled, and their
data were analyzed retrospectively. Inclusion criterion was
acute aortic dissection conﬁrmed by computed tomographyand Vascular Anesthesia, Vol 30, No 5 (October), 2016: pp 1272–1277
Fig 1. Flowchart of patients enrolled in the study.
Table 1. Characteristics of Patients
Total (N ¼ 151)
Stanfor
Surgery (n ¼ 7
Age (years) 50.3  13.5 60.9  14.5
Male (n, %) 106 (70.20) 47 (61.84)
Hypertension (n, %) 99 (65.56) 48 (63.16)
Diabetes (n, %) 12 (7.95) 6 (7.89)
Current smoker (n, %) 35 (23.18) 17 (22.37)
Coronary heart disease (n, %) 3 (1.99) 1 (1.32)
History of stroke (n, %) 8 (5.30) 4 (5.26)
History of heart failure (n, %) 4 (2.65) 3 (3.95)
Marfan’s syndrome (n, %) 18 (11.92) 14 (18.42)
Thyroid hormones
T3 (nmol/L) 1.0  0.4 1.0  0.4
T4 (nmol/L) 97.9  28.5 98.3  28.5
fT3 (pmoI/L) 3.8 (3.3, 4.2) 3.8 (3.2, 4.2
fT4 (pmoI/L) 11.3  3 11.9  3.2
TSH (mIU/L) 0.83 (0.49, 1.49) 0.8 (0.5, 1.5
Troponin I (mg/L) 0.02 (0.01, 0.36) 0.15 (0.01, 2
LDL (mmol/L) 2.5  0.9 2.2  0.8
Creatinine on admission (mmol/L) 75 (60, 102) 75 (57, 108
D-Dimer (mg/L) 5.16 (1.96, 13.72) 5.2 (2.8, 17
Platelet count (109/L) 175.8  63.8 172.7  69.5
Symptom duration (days) 1 (1, 2) 1 (1, 2)
Preoperative duration (days)* 2.5 (1, 10) 2.5 (1, 4.8)
Artery dissection involved to (n, %)
Carotid artery 48 (31.79) 39 (51.32)
Spinal cord vascular 3 (1.99) 2 (2.63)
Coronary artery 13 (8.61) 12 (15.79)
Renal artery 37 (24.50) 23 (30.26)
Mesenteric artery 19 (12.58) 11 (14.47)
Pericardial effusion 53 (35.10) 43 (56.58)
Acute kidney injury (n, %) 98 (64.90) 67 (88.16)
Stage 1 65 (43.05) 40 (52.63)
Stage 2 11 (7.28) 10 (13.16)
Stage 3 22 (14.57) 17 (22.37)
Postoperative renal failure needing
CRRT (n, %)*
9 (5.96) 8 (10.53)
CCU stay (days) 7 (3, 10) 7 (6, 13)
In-hospital mortality (n, %) 19 (12.6) 6 (7.9)
Abbreviations: CCU, cardiac care unit; CRRT, continuous renal replacem
fT4, free thyroxine; T3, triiodothyronine Cardiac care unit; T4, thyroxine; T
*For patients who underwent surgical treatment.
PREDICTING OUTCOMES IN AORTIC DISSECTION 1273angiography (CTA) (Fig 1). “Acute” referred to aortic dis-
section diagnosed within 2 weeks of symptom onset. The
exclusion criteria were history of overt thyroid disease and
thyroid hormone-interfering drug therapy, such as amiodarone,
thyroid hormone, dopamine, or glucocorticoid. The authors
also excluded patients with traumatic dissection and those with
a history of severe liver diseases or chronic renal failure.
Serum thyroid hormones, including thyroid stimulating
hormone (TSH), triiodothyronine (T3), free triiodothyronine
(fT3), thyroxine (T4), and free thyroxine (fT4) in addition to
other blood variables (eg, creatinine, serum low-density lip-
oprotein, D-dimer) were measured on the second morning
following patient admission. The reference ranges of thyroid
hormones in the authors’ laboratory were as follows: TSH,
0.34-5.60 mIU/L; T3, 1.34-2.73 nmol/L; fT3, 3.8-6.0 pmol/L;
T4, 78.38-157.40 nmol/L; and T4, 7.86-14.41 pmol/L. Echo-
cardiography was performed within 2 days of admission forWith Acute Aortic Dissection
d Type A (n ¼ 91) Stanford Type B (n ¼ 60)
p6) Conservative (n ¼ 15) Stent-graft (n ¼ 34) Conservative (n ¼ 26)
52.8  15.1 61.5  12.7 53.8  14.4 40.05
12 (80.00) 29 (85.29) 18 (69.23) 40.05
11 (73.33) 21 (61.76) 19 (73.08) 40.05
1 (6.67) 2 (5.88) 3 (11.54) 40.05
6 (40.00) 6 (17.65) 6 (23.08) 40.05
0 (0.00) 0 (0.00) 2 (7.69) 40.05
4 (26.67) 0 (0.00) 0 (0.00) o0.05
1 (6.67) 0 (0.00) 0 (0.00) 40.05
1 (6.67) 1 (2.94) 2 (7.69) 40.05
1.1  0.3 1.1  0.3 1.0  0.3 40.05
97.9  32 92.4  25.5 103.9  30.5 40.05
) 4.1 (3.8, 4.4) 3.9 (3.5, 4.3) 3.8 (3.3, 3.9) o0.05
10.7  3.1 10.5  3 10.8  2.1 o0.05
) 0.8 (0.4, 2.2) 0.8 (0.5, 1.3) 0.8 (0.5, 1.5) o0.05
.02) 0.03 (0.01, 0.21) 0.01 (0.01, 0.01) 0.02 (0.01, 0.02) o0.05
2.7  1.0 2.8  0.9 2.7  1.1 o0.05
) 70 (61, 114) 69.5 (60.8, 79.3) 84.5 (65, 106) 40.05
.1) 8.7 (2.2, 15.8) 3.5 (1.9, 7.9) 2.1 (1.1, 9.1) o0.05
184.7  53.7 184.6  60.0 168.4  57.6 40.05
1 (1, 2) 1 (1, 3) 1 (1, 1.3) 40.05
N/A 10 (3.8, 12.3) N/A o0.05
6 (40.00) 1 (2.94) 2 (7.69) o0.05
0 (0.00) 0 (0.00) 1 (3.85) 40.05
1 (6.67) 0 (0.00) 0 (0.00) o0.05
5 (33.33) 4 (11.76) 5 (19.23) 40.05
3 (20.00) 4 (11.76) 1 (3.85) 40.05
5 (33.33) 2 (5.88) 3 (11.54) o0.05
7 (46.67) 17 (50.00) 7 (26.92) o0.01
7 (46.67) 14 (41.18) 4 (15.38) o0.01
0 (0.00) 1 (2.94) 0 (0.00)
0 (0.00) 2 (5.88) 3 (11.54)
N/A 1 (2.94) N/A o0.05
2 (1, 6) 6 (3.8, 10) 5 (1, 6) o0.05
8 (53.3) 0 (0.0) 5 (19.2) o0.05
ent therapy; LDL, low-density lipoprotein; fT3, free triiodothyronine;
SH, thyroid-stimulating hormone.
Table 3. Predictors of In-hospital Mortality by Cox Analysis for
Patients Who Received Conservative Treatment
Predictors
Univariate Multivariate
HR
95% CI
p HR
95% CI
pLow Upper Low Upper
T3 0.26 0.03 2.00 0.20 0.01 0.00 0.22 0.00
D-Dimer 1.10 1.03 1.18 0.01 1.02 0.95 1.11 0.57
Pericardial
effusion
8.80 2.85 27.17 0.00 10.06 2.25 44.87 0.00
Stanford type A 4.11 1.33 12.71 0.01 10.74 2.28 50.70 0.00
Acute kidney
injury
1.84 1.15 2.93 0.01 2.29 1.06 4.92 0.03
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; T3,
triiodothyronine.
LINGZHI ET AL1274preoperative evaluation as well as diagnosis of pericardial
effusion or tamponade. All patients received appropriate treat-
ment with statins in addition to individualized maximal doses
of β-blockers by oral or intravenous infusion.
The rationale and strategy for treatment were determined by
thoracic surgeons according to the 2010 American Association
for Thoracic Surgery guidelines for the diagnosis and manage-
ment of thoracic aortic disease.18
This study was approved by the ethical committees of the
First Afﬁliated Hospital of Wenzhou Medical University. Patient
information was anonymized and deidentiﬁed prior to analysis.
Outcome Measurement
Data on in-hospital adverse events were collected, including
death from aortic dissection; rupture of dissecting aneurysm;
brain, spinal, coronary, or mesenteric artery dissection indicated
by CTA; acute organic dysfunction due to artery dissection such
as renal failure, stroke, or myocardial infarction; and pericardial
effusion or tamponade found by CT or echocardiography. Acute
kidney injury (AKI) and AKI staging were deﬁned as follows:
AKI stage 1: increase in serum creatinineZ1.5 times baseline
orZ26.5 μmol/L; stage 2: increase in serum creatinineZ2.0
times baseline; stage 3: increase in serum creatinineZ3 times
baseline orZ353.6 μmol/L). These deﬁnitions followed the
Kidney Disease Improving Global Outcomes (KDIGO) clinical
practice guideline for acute kidney injury.19
Statistical Analysis
Statistical analysis involved use of SPSS v18.0 for Win-
dows (SPSS Inc., Chicago, IL). Continuous variables were
expressed as mean  SD or median (25th-75th percentile);
categorical variables were expressed as a number (percentage).
Data were compared by Student t, ANOVA, rank-sum, or chi-
square test, as appropriate. The association of T3 level and in-
hospital adverse events was ascertained by binary logistic
regression and Cox multivariate survival analysis. Statistical
signiﬁcance was set at po 0.05.
RESULTS
Patient Characteristics
One hundred three patients who met exclusion criteria or
with incomplete data were excluded; 151 patients ultimatelyTable 2. Predictors of In-hospital Mortality by Cox Analysis
Predictors
Univariate Multivariate
HR
95% CI
p HR
95% CI
pLow Upper Low Upper
T3 0.27 0.07 0.94 0.04 0.07 0.01 0.43 0.00
TSH 1.27 1.12 1.43 0.00 0.99 0.84 1.16 0.86
D-Dimer 1.09 1.02 1.16 0.01 1.05 0.99 1.12 0.12
Pericardial
effusion
4.26 1.62 11.22 0.00 8.18 2.11 31.67 0.00
Conservative
treatment
7.31 2.76 19.38 0.00 82.12 12.49 540.09 0.00
Stanford type A 1.89 0.68 5.25 0.22 3.86 1.06 14.09 0.04
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; T3, triio-
dothyronine; TSH, thyroid-stimulating hormone.were included in this investigation. CTA scans were performed
in all patients to conﬁrm Stanford type of aortic dissection.
Patient enrollment and group are shown in Figure 1. Overall,
the mean age was 50.3 ( 13.5) years, and there were
signiﬁcantly more men than women (70.2%, po 0.05). More
than half of patients had a history of hypertension (65.56%).
Age, sex, symptom duration, and previous medical history
were not different among the 4 groups, except for history of
stroke. Thirty-eight patients had elevated troponin I, and all of
these had Stanford type-A dissections. D-dimer was also higher
in patients with Stanford type-A dissections compared with
patients who had Stanford type-B dissections.
On the basis of the normal ranges described previously, T3
was lower in 123 (81.5%) patients. T3 level did not differ
between Stanford type-A and -B dissections (0.99  0.39 v
1.03  0.29 nmol/L, p4 0.05), nor did it differ between
conservatively and nonconservatively treated patients
(1.04  0.28 v 0.99  0.38 nmol/L, p4 0.05). However, T3
levels were lower in nonsurvivors compared with survivors
(0.8  0.3 v 1.0  0.4 nmol/L, po 0.05). The baseline
characteristics of patients are shown in Table 1.Treatment and In-hospital Outcome
Among patients with Stanford type-A dissections, 76
(50.3%) underwent surgery, and 15 (9.9%) received conserva-
tive treatment. Surgical procedures included 43 (28.5%) aortic
replacements with or without descending aorta stent graft; 18
(11.9%) aortic valve, root, and ascending aorta replacements
with coronary artery re-implant; and 15 (9.9%) aortic valve,
root, and ascending aorta replacement with coronary artery
bypass. Among patients with Stanford type-B dissections, 34
(22.5%) were treated with stent-graft placement, and 26
(17.2%) received conservative treatment.
The total in-hospital mortality rate was 12.6%. Mortality
was higher in conservatively versus nonconservatively treated
patients (31.7% v 5.5%, po 0.01) but did not differ between
Stanford type-A and -B dissections (15.4% v 8.3%, p ¼ 0.20).
Mortality among patients who received conservative treatment
for Stanford type-A dissections was signiﬁcantly higher than
that of patients treated surgically for Stanford type-A dissec-
tions, as well as for patients treated conservatively and
Table 4. Predictors of In-hospital Mortality by Cox Analysis for Patients Who Received Nonconservative Treatment
Predictors
Univariate Multivariate
HR
95% CI
p HR
95% CI
pLow Upper Low Upper
T3 0.06 0.01 0.71 0.03 0.02 0.00 0.88 0.04
CCU stay 0.78 0.61 1.00 0.05 0.74 0.59 0.94 0.01
Postoperative renal replacement treatment 18.05 3.00 108.52 0.00 21.32 3.07 147.88 0.00
Abbreviations: CCU, cardiac care unit; CI, conﬁdence interval; HR, hazard ratio; T3, triiodothyronine.
PREDICTING OUTCOMES IN AORTIC DISSECTION 1275nonconservatively for Stanford type-B dissections (53.3% v
7.9%, 0.0%, 19.2%, respectively, po 0.05). No difference in
mortality was found among those 3 groups.
Ninety-eight patients (64.90%) experienced AKI during
hospitalization, including 22 patients with AKI stage 3 and 9
patients with postoperative acute renal failure and need for
continuous renal replacement therapy. The incidences of AKI,
AKI stage 3, and postoperative continuous renal replacement
therapy were signiﬁcantly higher in the surgically treated
Stanford type-A dissection group than in other groups.
Risk Factors for In-hospital Outcomes
On univariate Cox proportional hazards analysis, in-hospital
death was associated with T3 (HR 0.27, 95% CI 0.07-0.94,
po 0.05), TSH (HR 1.27, 1.12-1.43, po 0.01), D-dimer (HR
1.09, 1.02-1.16, p ¼ 0.01), pericardial effusion (HR 4.26, 1.62-
11.22, po 0.01), and conservative treatment (HR 7.31, 2.76-
19.38, po 0.01). After adjustment for the above risk factors as
well as Stanford type, multivariate Cox analyses conﬁrmed that
low T3 independently predicted in-hospital death (HR 0.07,
95% CI 0.01-0.43, po 0.01). Other risk factors were peri-
cardial effusion (HR 8.18, 2.11-31.67, po 0.01), conservative
treatment (HR 82.12, 12.49-540.09, po 0.01), and Stanford
type-A aortic dissection (HR 3.86, 1.06-14.09, po 0.05)
(Table 2).
In patients who received conservative treatment, T3 (HR
0.01, 0.00-0.22, po 0.01) as well as pericardial effusion (HR
10.06, 2.25-44.87, po 0.01), Stanford type A (HR 10.74,
2.28-50.70, po 0.01), and AKI (HR 2.29, 1.06-4.92,
p o 0.05) were predictors for in-hospital mortality (Table 3).
In nonconservatively treated patients, T3 (HR 0.02, 0.00-0.88,
p o 0.05), cardiac care unit stay (HR 0.74, 0.59-0.94,
p o 0.01), and postoperative renal replacement treatmentTable 5. Predictors of AKI Stage 3 by Logistic Regression
Predictors
Univariate Multivariate
OR
95% CI
p OR
95% CI
pLow Upper Low Upper
T3 0.05 0.01 0.24 0.00 0.1 0.02 0.51 0.01
D-Dimer 1.11 1.04 1.18 0.00 1.09 1.02 1.18 0.02
Pericardial effusion 3.21 1.27 8.13 0.01 1.47 0.45 4.86 0.53
LDL 0.47 0.26 0.85 0.01 0.77 0.4 1.47 0.42
Conservative
treatment
0.38 0.11 1.35 0.13 0.55 0.13 2.41 0.43
Stanford type 2.53 0.88 7.27 0.09 0.92 0.22 3.89 0.91
Abbreviations: CI, conﬁdence interval; LDL, low-density lipoprotein;
OR, odds ratio; T3, triiodothyronine.(HR 21.32, 3.07-147.88, po 0.01) were predictors for in-
hospital mortality (Table 4).
T3 level was lower for patients with AKI stage 3
(0.72  0.38 nmol/L) than stage 1 (1.06  0.34 nmol/L), stage
2 (1.12  0.43 nmol/L) or patients without AKI (0.72  0.38
nmol/L) (po 0.01). T3 level was associated with AKI stage 3
(OR 0.05, 95% CI 0.01-0.24, po 0.01). Other signiﬁcant risk
factors found by univariate logistic regression included
D-dimer, pericardial effusion, and low-density lipoprotein.
After adjustment for the above risk factors as well as Stanford
type and conservative treatment, multivariate logistic regression
indicated T3 (OR 0.1, 95% CI 0.02-0.51, po 0.01), and
D-dimer (OR 1.09, 95% CI 1.02-1.18, po 0.05) were
associated with in-hospital acute renal failure (Table 5).DISCUSSION
The major ﬁnding and innovation of the present study were
that the authors found that T3 was lower in nonsurvivors versus
survivors of acute aortic dissection. T3 independently predicted
in-hospital mortality and acute renal failure for patients with
acute aortic dissection.
In the present study, in-hospital mortality due to acute aortic
dissection varied from 0% to 53.3%, mainly depending on
whether surgical or medical treatment was performed. Risk
factors for in-hospital mortality differed between surgically and
medically treated patients. Nevertheless, in both medically and
surgically treated patients, univariate and multivariate analyses
demonstrated that T3 was an independent risk factor for in-
hospital mortality. To the best of the authors’ knowledge, no
study has investigated thyroid hormones in acute aortic
dissection outcome. This research provided a new biomarker
for risk classiﬁcation and an outcome predictor.
Previous studies have proven that surgical management
could greatly decrease mortality compared with medical treat-
ment.20,21 Thus, it generally was advocated that acute aortic
dissection should be managed surgically to improve outcomes.
In the current study, mortality of surgically treated Stanford
type-A dissection was similar to that of Stanford type-B
dissection, and Stanford type-A dissection was not a signiﬁcant
risk factor for surgically treated patients, which also agreed
with previous studies. In addition, T3 independently predicted
in-hospital mortality despite treatment strategy.
The pathophysiologic mechanism underlying the association
between lowered T3 and critical illness has not been fully
elucidated, but several theories have been proposed. Some
researchers suggested that T3 was lowered by thyroid
hormone-interfering drugs such as glucocorticoids, dopamine,
LINGZHI ET AL1276and amiodarone or propranolol,22-25 which were not found in
patients in the current study. Some researchers suggested that
in the setting of infectious or inﬂammatory diseases, T3
synthesis was inhibited by free fatty acids or cytokines,26,27
which needs further investigation in the setting of aortic
dissection.
The authors also found low T3 associated with AKI and
AKI staging. AKI could be caused by general circulatory
collapse or renal malperfusion due to renal artery dissection. In
the present study, renal artery dissection was found in only
about one ﬁfth of all included patients and nearly two thirds of
all included patients experienced AKI. It was conceivable that
quite a few instances of AKI were caused by hypotension,
systemic malperfusion, and shock. Previous studies associated
low T3 with vulnerable renal function and worsened renal
disease outcome; however, these studies all focused on chronic
subclinical or clinical hypothyroidism in chronic renal failure
or kidney transplantation.28,29 More investigations are needed
to reveal the underlying association between acute low T3 and
acute renal injury.
Some limitations of the current study need to be mention-
ed. First, T3 could be signiﬁcantly lower in patients withpre-existing subclinical hypothyroidism, which the authors
were not able to exclude. Given that the prevalence of
subclinical hypothyroidism in the healthy population
ranges from 2.8% to 7.5%,30,31 the incidence of patients
with both acute aortic dissection and subclinical hypo-
thyroidism should be quite small, and the authors assumed
the effect was negligible. Second, because all patients
underwent CTA, the authors could not exclude AKI caused
by contrast-induced nephropathy (CIN), although the inci-
dence of CIN was quite low in patients without chronic
renal disease. Last, this was a single-center retrospective
study with a relatively small study population. Therefore, a
prospective large-scale multicenter study is required to
conﬁrm the authors’ results as well as to predict the role
of T3 in long-term survival.CONCLUSIONS
Serum T3 provides an additional risk factor to predict acute
renal failure and in-hospital mortality in patients with aortic
dissection.REFERENCES1. Erbel R, Oelert H, Meyer J, et al: Effect of medical and surgical
therapy on aortic dissection evaluated by transesophageal echocardiog-
raphy. Implications for prognosis and therapy. The European Cooper-
ative Study Group on Echocardiography. Circulation 87:
1604-1615, 1993
2. Westaby S, Saito S, Katsumata T: Acute type A dissection:
Conservative methods provide consistently low mortality. Ann Thorac
Surg 73:707-713, 2002
3. Winnerkvist A, Lockowandt U, Rasmussen E, et al: A prospective
study of medically treated acute type B aortic dissection. Eur J Vasc
Endovasc Surg 32:349-355, 2006
4. Zhang J, Jiang Y, Gao C, et al: Risk factors for hospital death in
patients with acute aortic dissection. Heart Lung Circ 24:348-353, 2015
5. Mehta RH, Suzuki T, Hagan PG, et al: Predicting death in patients
with acute type A aortic dissection. Circulation 105:200-206, 2002
6. Wen D, Zhou XL, Li JJ, et al: Biomarkers in aortic dissection.
Clin Chim Acta 412:688-695, 2011
7. Kumar KV, Kapoor U, Kalia R, et al: Low triiodothyronine
predicts mortality in critically ill patients. Indian J Endocrinol Metab
17:285-288, 2013
8. Ture M, Memis D, Kurt I, et al: Predictive value of thyroid
hormones on the ﬁrst day in adult respiratory distress syndrome patients
admitted to ICU: Comparison with SOFA and APACHE II scores. Ann
Saudi Med 25:466, 2005
9. Meyer S, Schuetz P, Wieland M, et al: Low triiodothyronine
syndrome: A prognostic marker for outcome in sepsis? Endocrine 39:
167-174, 2011
10. Hifumi T, Okada I, Kiriu N, et al: Thyroid hormone alterations in
trauma patients requiring massive transfusion: An observational study.
World J Emerg Med 5:270-274, 2014
11. Ozcan KS, Osmonov D, Toprak E, et al: Sick euthyroid
syndrome is associated with poor prognosis in patients with STEMI
undergoing primary percutaneous intervention. Cardiol J 21:
238-244, 2014
12. Auer J, Berent R, Weber T, et al: Thyroid function is associated
with presence and severity of coronary atherosclerosis. Clin Cardiol 26:
569-573, 200313. Economidou F, Douka E, Tzanela M, et al: Thyroid function
during critical illness. Hormones 10:117-124, 2011
14. Sumita S, Ujike Y, Namiki A, et al: Suppression of the thyrotropin
response to thyrotropin-releasing hormone and its association with severity
of critical illness. Crit Care Med 22:1603-1609, 1994
15. Rothwell PM, Lawler PG: Prediction of outcome in intensive
care patients using endocrine parameters. Crit Care Med 23:
78-83, 1995
16. Chinga-Alayo E, Villena J, Evans AT, et al: Thyroid hormone
levels improve the prediction of mortality among patients admitted to
the intensive care unit. Intensive Care Med 31:1356-1361, 2005
17. Gutierrez PS, Pereira MA, Oliveira RC, et al: Thyroid hormone
levels in patients with aortic dissection: comparison with controls and
correlation with the percentage of the aortic media composed of
myxoid deposits. Arq Bras Cardiol 82(134-138):129-133, 2004
18. Hiratzka LF, Bakris GL, Beckman JA, et al: 2010 ACCF/AHA/
AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diag-
nosis and management of patients with thoracic aortic disease. A report
of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines, American Association
for Thoracic Surgery, American College of Radiology, American
Stroke Association, Society of Cardiovascular Anesthesiologists, Soci-
ety for Cardiovascular Angiography and Interventions, Society of
Interventional Radiology, Society of Thoracic Surgeons, and Society
for Vascular Medicine. J Am Coll Cardiol 55:e27-e129, 2010
19. Khwaja A: KDIGO clinical practice guidelines for acute kidney
injury. Nephron Clin Pract 120:c179-c184, 2012
20. Hagan PG, Nienaber CA, Isselbacher EM, et al: The Interna-
tional Registry of Acute Aortic Dissection (IRAD): New insights into
an old disease. JAMA 283:897-903, 2000
21. Qin YL, Deng G, Li TX, et al: Treatment of acute type-B aortic
dissection: Thoracic endovascular aortic repair or medical management
alone? JACC Cardiovasc Interv 6:185-191, 2013
22. Chopra IJ, Williams DE, Orgiazzi J, et al: Opposite effects of
dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse
T3) and 3,3'5-triiodothyronine (T3). J Clin Endocrinol Metab 41:
911-920, 1975
PREDICTING OUTCOMES IN AORTIC DISSECTION 127723. Kaptein EM, Spencer CA, Kamiel MB, et al: Prolonged
dopamine administration and thyroid hormone economy in normal
and critically ill subjects. J Clin Endocrinol Metab 51:387-393, 1980
24. Burger A, Dinichert D, Nicod P, et al: Effect of amiodarone on
serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyro-
tropin. A drug inﬂuencing peripheral metabolism of thyroid hormones.
J Clin Invest 58:255, 1976
25. Saunders J, Hall SE, Crowther A, et al: The effect of propranolol
on thyroid hormones and oxygen consumption in thyrotoxicosis. Clin
Endocrinol 9:67-72, 1978
26. Chopra IJ, Huang TS, Beredo A, et al: Evidence for an inhibitor
of extrathyroidal conversion of thyroxine to 3, 5, 3'-triiodothyronine in
sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab
60:666-672, 198527. van der Poll T, Romijn JA, Wiersinga WM, et al: Tumor necrosis
factor: A putative mediator of the sick euthyroid syndrome in man.
J Clin Endocrinol Metab 71:1567-1572, 1990
28. Papalia T, Greco R, Lofaro D, et al: Thyroid status and
kidney transplantation outcomes. Transplant Proc 43:1042-1044,
2011
29. Iglesias P, Díez JJ: Thyroid dysfunction and kidney disease. Eur
J Endocrinol 160:503-515, 2009
30. Tunbridge WM, Evered DC, Hall R, et al: The spectrum of
thyroid disease in a community: The Whickham survey. Clin Endo-
crinol 7:481-493, 1977
31. Vanderpump MP, Tunbridge WM, French JM, et al: The
incidence of thyroid disorders in the community: A twenty-year
follow-up of the Whickham Survey. Clin Endocrinol 43:55-68, 1995
